GRN and frontotemporal degeneration

What GRN does

GRN provides instructions for making a protein called progranulin. Progranulin is involved in cell maintenance, immune signaling, inflammation, and the function of lysosomes, which help cells process and recycle material.

Most GRN variants that cause FTD reduce the amount of functioning progranulin. One working copy of the gene does not produce enough protein for normal function over a lifetime. The precise steps from reduced progranulin to degeneration of particular brain networks are still being studied.

GRN-related FTD is usually associated with abnormal TDP-43 protein in the brain, not tau. The gene and the clinical syndrome therefore provide related but different kinds of information about the disease process.

What symptoms can look like

GRN-related disease can begin with changes in behavior, judgment, motivation, or personality. It can also begin with progressive difficulty producing or understanding language.

Some people develop movement features such as stiffness, slowness, limb apraxia, dystonia, or corticobasal syndrome. Memory and other cognitive functions can also be affected. Brain imaging may show an asymmetric pattern, with one side or region affected more than another.

These are tendencies, not a checklist that identifies the gene. A person with a GRN pathogenic variant may receive a diagnosis of behavioral-variant FTD, primary progressive aphasia, corticobasal syndrome, or another overlapping clinical syndrome. Relatives with the same variant may not begin in the same way.

How GRN is inherited

GRN-related FTD is usually inherited in an autosomal dominant manner. If a person carries a pathogenic GRN variant, each child has a 50 percent chance of inheriting that variant.

GRN has age-related and sometimes reduced penetrance. The chance of developing symptoms rises with age, but a positive result does not provide an exact age of onset. Some carriers remain free of symptoms into later life.

A family history may appear negative because a relative died young, symptoms were attributed to another diagnosis, the family is small, or a carrier did not develop recognizable disease. Rarely, a pathogenic variant may arise for the first time in one person.

What testing needs to show

A diagnosis of GRN-related FTD requires a pathogenic or likely pathogenic variant that fits the clinical context. A variant of uncertain significance does not establish the diagnosis.

Testing should include methods capable of finding both small sequence variants and deletions or duplications involving GRN. The details vary by laboratory. A negative result on a panel that did not include deletion or duplication analysis may be incomplete.

When possible, testing begins with a relative who has symptoms. If a pathogenic GRN variant is confirmed, unaffected adult relatives can choose whether to have targeted predictive testing for the exact familial variant.

What a positive result can and cannot tell us

A confirmed pathogenic result can:

• explain the likely cause of FTD in a symptomatic person;
• establish an autosomal dominant family pattern;
• allow targeted testing for adult relatives who want it;
• support eligibility for some GRN-focused research studies or trials;
• inform reproductive and long-term planning.

It usually cannot predict which symptom will come first, the exact age of onset, or the pace of change. It also does not indicate the current stage of disease in an unaffected carrier.

Predictive testing deserves preparation

An adult relative who does not have symptoms faces a different question from the person being diagnosed. Predictive testing may replace one uncertainty with information that affects family relationships, emotional health, planning, insurance considerations, and research choices.

Genetic counseling before and after testing helps clarify what each result would mean. The purpose is not to encourage or discourage testing. It is to make the decision informed and voluntary.

Predictive testing of children for adult-onset GRN-related FTD is generally not recommended when the result would not change care during childhood.

Research is becoming more gene-specific

GRN is an active area of therapeutic research. Several approaches aim to restore or increase progranulin or address downstream cell biology. Eligibility for a gene-specific study may require clinical confirmation of the familial variant.

Research participation is separate from clinical care, and an experimental therapy is not established treatment. A genetics or FTD specialist can explain which observational studies or trials are appropriate for a particular family.